Who is sponsoring NCT04179084?

NCT04179084 is sponsored by Chinese PLA General Hospital.

What drugs are being tested in NCT04179084?

Interventions in NCT04179084: fruquintinib, Sintilimab.

What condition does NCT04179084 study?

NCT04179084 studies Metastasis Colorectal Cancer.

Is NCT04179084 still recruiting?

NCT04179084 is currently status unknown. Last updated 26 November 2019.

Last reviewed 2019-11-26 · How we verify

NCT04179084

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase II Study to Evaluate the Efficacy and Safety of Fruquintinib Plus Sintilimab as Third-line Therapy for Colorectal Cancer

Status unknown Phase 2 Last updated 26 November 2019

What this trial tests

Phase 2 trial testing fruquintinib in Metastasis Colorectal Cancer in 30 participants. Status unknown.

Timeline

28 August 2019

Primary endpoint
1 March 2020

1 May 2020

Quick facts

Lead sponsor	Chinese PLA General Hospital
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	28 August 2019
Primary completion	1 March 2020
Estimated completion	1 May 2020
Sites	1 location across China

Drugs / interventions tested

fruquintinib — full drug profile →
Sintilimab — full drug profile →

Conditions studied

Metastasis Colorectal Cancer — all drugs for Metastasis Colorectal Cancer →

Sponsor

Chinese PLA General Hospital

Who can join

18 and older, any sex, with Metastasis Colorectal Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a single center, investigator initiated phase II clinical study to evaluate the efficacy and safety of fruquintinib plus Sintilimab as third-line therapy for colorectal cancer

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Recent updates on Sintilimab in solid tumor immunotherapy.
Liu X, Yi Y. · · 2020 · cited 35× · PMID 33292551 · DOI 10.1186/s40364-020-00250-z
Up-and-Coming Experimental Drug Options for Metastatic Colorectal Cancer.
Cimino SK, Eng C. · · 2020 · cited 5× · PMID 33204182 · DOI 10.2147/jep.s259287

Verify or expand the search:

Other trials of fruquintinib

Trials testing the same drug.

NCT07270991 — Trifluridine/Tipiracil + Fruquintinib Versus Trifluridine/Tipiracil Alone for Metastatic Oeso-gastric Adenocarcinoma · Phase 3 · recruiting
NCT06584032 — Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer · Phase 3 · recruiting
NCT05993702 — TAS-102 in Combination With Regorafenib or Fruquintinib for Third-line and Above Advanced Colorectal Cancer · unknown
NCT05941325 — A Single-arm, Open-label, Single-center Prospective Study of Fruquintinib Combined With Envafolimab in the Treatment of · Phase 2 · recruiting

Other Chinese PLA General Hospital trials

Trials by the same sponsor.

NCT07294755 — The Impact of Intrapleural Block on Postoperative Pain Caused by Drainage Tubes After Thoracoscopic Surgery · NA · not yet recruiting
NCT07536607 — Predictive Role of Photon Counting Computed Tomography in Acute Coronary Syndrom Patients · not yet recruiting
NCT07489157 — Real-Time End-Tidal Carbon Dioxide Monitoring for Early Warning of Hypoxemia in Painless Gastrointestinal Endoscopy · NA · not yet recruiting
NCT07494981 — Individualized Precision Therapy With Ceftazidime and Avibactam Guided by PK/PD in Geriatric Populations · not yet recruiting
NCT07496008 — Individualized Precision Isavuconazole Therapy Guided by PK/PD Principles for the Geriatric Population · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04179084 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chinese PLA General Hospital
Last refreshed: 26 November 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04179084.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing